Skip to content

Clinical trials

Phase 2 Genetic Diseases, Inborn trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Genetic Diseases, Inborn Phase: Phase 2 Country / region: United Kingdom Clear all

15 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20101
20112
20121
20141
20182
20191
20201
20211
20221
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed9
Enrolling by invitation3
Recruiting1
Terminated1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novartis Pharmaceuticals3
QED Therapeutics, a BridgeBio company3
Alexion Pharmaceuticals, Inc.1
Alnylam Pharmaceuticals1
BioMarin Pharmaceutical1
Boston University1
CSL Behring1
Forma Therapeutics, Inc.1
Imperial College London1
Novo Nordisk A/S1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Genetic Diseases, Inborn15
Musculoskeletal Diseases5
Bone Diseases4
Osteochondrodysplasias4
Achondroplasia3
Dwarfism3
Fragile X Syndrome3
Mucopolysaccharidosis IV3
Anemia2
Anemia, Sickle Cell2

Trials

Showing 1 to 15 of 15. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.